| Dr Jacquelin Gouniai, LPC | |
|
121 North Sabana Drive Detcha Court, Barrigada Heights, GU 96913 | |
| (671) 688-8159 | |
| Not Available |
| Full Name | Dr Jacquelin Gouniai |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 121 North Sabana Drive Detcha Court, Barrigada Heights, Guam |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720618499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | LPC-156 (Guam) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jacquelin Gouniai, LPC Po Box 315377, Tamuning, GU 96931-3277 Ph: (671) 688-8159 | Dr Jacquelin Gouniai, LPC 121 North Sabana Drive Detcha Court, Barrigada Heights, GU 96913 Ph: (671) 688-8159 |
News Archive
A single treatment of 8 gray (Gy-a unit of measure of absorbed radiation dose) of radiation appears to be as effective in palliating painful bone metastases as the current U.S. standard treatment course of 30 Gy delivered in 10 daily treatments, according to a new study in the June 1 issue of the Journal of the National Cancer Institute.
An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England Journal of Medicine. The now published results were previously presented at the American Diabetes Association's 71st Scientific Sessions in San Diego, California, USA, on June 28, 2011.
atients with relapsed or refractory follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than patients who do not receive this treatment, according to a meta-analysis of randomized trials in the February 10 online issue of the Journal of the National Cancer Institute.
AppDynamics, Inc.™, the next-generation Application Performance Management (APM) company, today announced that it has closed its Series B round of financing, and had raised $11 million. The round is co-led by existing Series A investors Lightspeed Venture Partners and Greylock Partners, and will support the company's continued expansion as it takes advantage of market demand for next-generation application performance management (APM). To date, the company has received $16.5 million in venture funding.
› Verified 3 days ago